Cellectis ADR (CLLS) Unusual Options Activity Today

Checking CLLS unusual options activity helps you spot when traders are making outsized bets on Cellectis ADR before the broader market catches on. Cellectis ADR's unusual options activity flags contracts trading at multiples of their average daily volume, often signaling that informed money is positioning ahead of a catalyst. Use our scanner to monitor CLLS unusual options activity today and surface the prints that deserve a second look.

Unusual options flow typically refers to trades where volume vastly exceeds open interest at a given strike, or where total contract volume on a name spikes well above its norm. Watching CLLS unusual options flow today can reveal large block trades, sweeps across exchanges, and aggressive directional bets. Tracking CLLS unusual options volume across calls and puts helps you separate hedging activity from genuinely speculative positioning, and CLLS unusual options flow data becomes especially valuable around earnings, product launches, and macro events.

Cellectis S.A., a clinical stage biotechnological company, develops immuno-oncology products based on gene-edited T-cells that express chimeric antigen receptors to target and eradicate cancer cells. It operates through two segments, Therapeutics and Plants. The company is developing UCART19, an allogeneic T-cell product candidate for the treatment of CD19-expressing hematologic malignancies, such as acute lymphoblastic leukemia; ALLO-501 and ALLO-501A to treat relapsed/refractory diffuse large B-cell lymphoma and follicular lymphoma; ALLO-316 for the treatment of Renal Cell Carcinoma; UCART123 for the treatment of acute myeloid leukemia; and UCART22 to treat B-cell acute lymphoblastic leukemia.

It is also developing UCARTCS1 and ALLO-715 for the treatment of multiple myeloma. The company has strategic alliances with Allogene Therapeutics, Inc.; Les Laboratoires Servier; The University of Texas M.D. Anderson Cancer Center; and Iovance Biotherapeutics, as well as a strategic research and development collaboration with Cytovia Therapeutics, Inc. Cellectis S.A. was founded in 1999 and is headquartered in Paris, France.

Catalysts rarely arrive without a footprint, and CLLS unusual options activity is often where that footprint shows up first. Our scanner tracks Cellectis ADR's unusual options flow in real time, ranks prints by volume-to-open-interest, premium spent, and aggressor side, and separates real conviction from noise. Whether you're looking at CLLS unusual options volume on the call side or chasing put sweeps, Cellectis ADR's unusual options flow today is one click away, so put it on your radar before the headlines hit.